Effect of sodium ‐glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes
ConclusionWe suggest that this metabolic improvement might be related to SIRT1 and AMPK pathway in T2DM. But empagliflozin is thought to have more advantage to prevent hepatic steatosis than voglibose in T2DM.
Source: Journal of Cellular Biochemistry - Category: Biochemistry Authors: Ji ‐Won Kim,
Ye‐Jee Lee,
Young‐Hye You,
Min Kyong Moon,
Kun‐Ho Yoon,
Yu‐Bae Ahn,
Seung‐Hyun Ko Tags: RESEARCH ARTICLE Source Type: research
More News: Biochemistry | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Genetics | Jardiance | Liver | Sodium | Urology & Nephrology